Investment Analysts’ Recent Ratings Updates for Olema Pharmaceuticals (OLMA)

A number of firms have modified their ratings and price targets on shares of Olema Pharmaceuticals (NASDAQ: OLMA) recently:

• 8/13/2026 – Olema Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $52.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – Olema Pharmaceuticals had its price target lowered by HC Wainwright from $38.00 to $36.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Olema Pharmaceuticals had its price target lowered by Citigroup Inc. to $59.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Olema Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/25/2026 – Olema Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/17/2026 – Olema Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/12/2026 – Olema Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.

Insider Buying and Selling

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the sale, the director owned 715,270 shares in the company, valued at $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 12.56% of the stock is currently owned by insiders.

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.